Ocera Therapeutics (OCRX) Misses Q1 EPS by 3c

Ocera Therapeutics (NASDAQ: OCRX) reported Q1 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $33 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• Meta to pay up to $16.68 billion in mass social media settlement
• Okta, Inc. (OKTA) Tops Q2 EPS by 8c; offers guidance
• CrowdStrike Holdings Inc. (CRWD) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY Guidance